Amneal Pharmaceuticals (AMRX) Total Current Liabilities (2017 - 2026)

Amneal Pharmaceuticals has reported Total Current Liabilities for 10 years, with the latest figure at $883.2 million in Q2 2026.

• On a quarterly basis, Total Current Liabilities fell 20.23% year-over-year to $883.2 million in Q2 2026; TTM through Jun 2026 was $883.2 million, a 20.23% decrease from a year earlier, with the FY2025 full-year figure at $881.6 million, down 21.96% from the prior year.
• Total Current Liabilities was $883.2 million for Q2 2026 at Amneal Pharmaceuticals, up from $728.0 million in the prior quarter.
• The five-year high for Total Current Liabilities was $1.1 billion in Q4 2024, with the low at $602.0 million in Q1 2022.
• Average Total Current Liabilities over 5 years is $887.0 million, with a median of $854.4 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: Total Current Liabilities surged 47.59% in 2022, then plunged 32.33% in 2026.
• Over 5 years, Total Current Liabilities stood at $752.8 million in 2022, then grew by 12.46% to $846.6 million in 2023, then surged by 33.45% to $1.1 billion in 2024, then slipped by 21.96% to $881.6 million in 2025, then climbed by 0.18% to $883.2 million in 2026.
• The last three Total Current Liabilities figures came in at $883.2 million (Q2 2026), $728.0 million (Q1 2026), and $881.6 million (Q4 2025), per Business Quant data.